Skip to main content
OpenTrials
Completed

NCT Number: NCT00681486

Ghrelin - A Possible Opportunity to Improve Appetite

The study is designed to evaluate whether ghrelin treatment can improve appetite in weight losing cancer patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Department of surgery, Sahlgrenska University Hospital

Gothenburg, 413 45, Sweden

About this study

Randomized study with follow up evaluations each month until preterminal state. Cancer patients will be randomised to either high dose or low dose of active treatment given as daily injection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Weight loss

Exclusion criteria

  • Diabetes

Treatment and study plan

Ghrelin

Drug

High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.

Primary outcomes

  1. Food intake

    Time frame: June 2008

Sponsors and collaborators

Lead sponsor

Göteborg University

Other

Collaborators

  • Medical Research Council
  • Swedish Cancer Foundation

Registry information

Official study title

Ghrelin - A Possible Opportunity to Improve Appetite, Nutritional State, Metabolic Integrity and Physical Functioning in Cancer Patients With Progressive Weight Loss

Acronym: Phase 3

Important dates

Study start
2003
Primary completion
2008
Study completion
2008
First posted
May 21, 2008
Registry last updated
Aug 21, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.